



Journal Homepage: [-www.journalijar.com](http://www.journalijar.com)

INTERNATIONAL JOURNAL OF ADVANCED RESEARCH (IJAR)

Article DOI:10.21474/IJAR01/22632
DOI URL: <http://dx.doi.org/10.21474/IJAR01/22632>



RESEARCH ARTICLE

PULMONARY METASTASES FROM RENAL CELL CARCINOMA: CLINICAL FEATURES AND THERAPEUTIC MANAGEMENT

Lamia Aalaoui, Rachid Tanz and Hassan Errihani

Manuscript Info

Manuscript History

Received: 10 November 2025

Final Accepted: 12 December 2025

Published: January 2026

Key words:-

Renal cell carcinoma; Pulmonary metastases; Immunotherapy; Targeted therapy; Oligometastatic disease.

Abstract

Renal cell carcinoma (RCC) is characterized by a high metastatic potential, with the lung representing the most frequent site of dissemination in patients with advanced disease. Pulmonary metastases play a central role in prognostic assessment and therapeutic decision-making. Over the past decade, major advances in immunotherapy and targeted therapies have profoundly transformed the management of metastatic RCC. This narrative review provides an overview of the biological behavior, clinical presentation, prognostic implications, and therapeutic management of pulmonary metastases from RCC. Available evidence suggests that pulmonary metastases exhibit distinct clinical characteristics, including enhanced sensitivity to immunotherapy-based combinations compared with other visceral metastatic sites. Immunotherapy–tyrosine kinase inhibitor combinations and dual immune checkpoint blockade now constitute the cornerstone of first-line treatment. In selected patients with lung-dominant oligometastatic disease, the integration of local treatment strategies such as pulmonary metastasectomy or stereotactic body radiotherapy may result in prolonged disease control. Multidisciplinary and individualized management remains essential to optimize clinical outcomes.

"© 2026 by the Author(s). Published by IJAR under CC BY 4.0. Unrestricted use allowed with credit to the author."

Introduction:-

Renal cell carcinoma accounts for approximately 2–3% of all adult malignancies worldwide and represents the most common primary cancer of the kidney (1). Clear cell carcinoma is the predominant histological subtype. Despite curative-intent surgery for localized disease, a substantial proportion of patients will develop metastatic relapse during follow-up (2). The lung is the most frequent site of metastasis, observed in nearly half of patients with advanced disease (2). Pulmonary involvement significantly influences prognosis and therapeutic strategy, particularly in the era of immunotherapy-based treatments (3).

Clinically, pulmonary metastases differ from other visceral metastatic sites by their often indolent behavior, higher sensitivity to systemic therapies, and more favorable prognostic implications compared with liver or bone involvement (4,5). These characteristics make pulmonary metastatic RCC a distinct clinical entity with specific therapeutic considerations, particularly in the era of immunotherapy-based treatments(5).

Methods:-

This narrative review was based on a structured literature search conducted using PubMed and Scopus databases. Publications published between January 2010 and March 2025 were considered. The search strategy included combinations of the following keywords: “renal cell carcinoma”, “pulmonary metastases”, “lung metastases”, “immunotherapy”, “immune checkpoint inhibitors”, “tyrosine kinase inhibitors”, and “oligometastatic disease”.

Priority was given to phase III randomized clinical trials, international guidelines, systematic reviews, and large retrospective series. Case reports and small case series were excluded unless they provided unique clinical insights relevant to pulmonary metastatic renal cell carcinoma.

Biological and Clinical Characteristics of Pulmonary Metastases:

Pulmonary metastases from RCC occur primarily through hematogenous dissemination via the renal vein and inferior vena cava (6). Radiological presentations include solitary or multiple pulmonary nodules and, less frequently, diffuse parenchymal involvement. Clinically, pulmonary metastases are often asymptomatic and detected incidentally during routine imaging (2). When present, symptoms may include cough, dyspnea, chest pain, or hemoptysis. RCC is characterized by an unpredictable clinical course, including the possibility of late metastatic recurrence many years after initial treatment (7).

Prognostic Implications:

Prognostic evaluation in metastatic RCC is commonly based on the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria, which incorporate clinical and laboratory parameters (8). Patients are stratified into favorable, intermediate, and poor risk groups, guiding treatment decisions. Several studies have demonstrated that patients with lung-dominant metastatic disease have more favorable outcomes compared with those with liver or bone metastases, even in the immunotherapy era (4,9).

Systemic Treatment Strategies:

The treatment landscape of metastatic RCC has evolved substantially with the introduction of immune checkpoint inhibitors. Dual immunotherapy with nivolumab plus ipilimumab has demonstrated durable overall survival benefit, particularly in patients with intermediate- and poor-risk disease (10). In addition, combinations of immunotherapy with tyrosine kinase inhibitors, such as pembrolizumab plus axitinib, nivolumab plus cabozantinib, and pembrolizumab plus lenvatinib, have shown high response rates and rapid tumor shrinkage (11–13). These regimens are particularly relevant for patients with pulmonary metastases requiring prompt disease control. Subsequent lines of therapy may include targeted agents depending on prior treatment exposure and disease kinetics (3). A proposed therapeutic algorithm for the management of pulmonary metastatic renal cell carcinoma is presented in Figure 1.

Local Treatment of Oligometastatic Pulmonary Disease:

The concept of oligometastatic disease has gained increasing interest in RCC (14). In selected patients with a limited number of lung metastases and controlled primary tumors, local treatment approaches such as pulmonary metastasectomy or stereotactic body radiotherapy (SBRT) may offer prolonged disease control (15,16). Retrospective series have reported favorable long-term survival following complete resection of pulmonary metastases (16). SBRT provides an effective non-invasive alternative with high local control rates for pulmonary lesions (15).

It is important to emphasize that evidence supporting pulmonary metastasectomy and stereotactic body radiotherapy is largely derived from retrospective or small prospective series. Consequently, local treatment strategies should be considered only in highly selected patients and discussed within multidisciplinary tumor boards, acknowledging the current lack of randomized prospective data in pulmonary oligometastatic RCC.

Summary of Key Studies:

The principal studies evaluating systemic and local treatment strategies in patients with pulmonary metastatic RCC are summarized in Table 1.

Discussion:-

Pulmonary metastases represent the most frequent metastatic manifestation of RCC and constitute a clinically distinct subgroup within metastatic disease. Compared with other visceral metastatic sites, lung involvement has consistently been associated with more favorable outcomes, including higher response rates to systemic therapies

and prolonged survival (4,9). This observation suggests organ-specific tumor–host interactions that influence therapeutic sensitivity. The introduction of immunotherapy has profoundly reshaped the management of metastatic RCC. Both dual immune checkpoint blockade and immunotherapy–tyrosine kinase inhibitor combinations have demonstrated robust efficacy, with particularly high response rates observed in pulmonary lesions (10,13). Subgroup analyses indicate that lung metastases often exhibit deeper and more durable responses than liver or bone metastases, which are commonly associated with poorer prognosis (4,6).

Several biological hypotheses may explain the favorable behavior of pulmonary metastases. The lung is a highly vascularized and immunologically active organ, potentially facilitating immune cell infiltration and antitumor immune responses (4). In addition, pulmonary metastases are frequently detected early through routine imaging, allowing timely therapeutic intervention. Although predictive biomarkers remain limited, these factors may collectively contribute to improved outcomes in lung-dominant disease (15). The management of patients with pulmonary metastatic RCC should be individualized. Immunotherapy–tyrosine kinase inhibitor combinations are particularly suitable for patients requiring rapid tumor shrinkage, such as those with symptomatic disease or compromised respiratory function (9–11). Conversely, dual immunotherapy may offer durable disease control and treatment-free intervals in selected patients with limited tumor burden (8). The concept of oligometastatic pulmonary disease further expands therapeutic options, as local treatments may achieve prolonged disease control when integrated with effective systemic therapy (12,14). Despite these advances, several challenges remain. Most randomized trials were not designed to assess lung-specific outcomes as primary endpoints, limiting definitive conclusions. The optimal sequencing of therapies after progression on immunotherapy-based regimens remains uncertain, and evidence supporting local treatment strategies is largely retrospective (12,14). Furthermore, the absence of robust predictive biomarkers continues to limit personalized treatment selection (17).

Clinical Implications:-

Recognition of lung-dominant metastatic RCC is important in daily clinical practice. Pulmonary metastases often respond favorably to modern systemic therapies, and treatment discontinuation should be approached cautiously in cases of suspected pseudo-progression (17). Early multidisciplinary evaluation is recommended, particularly in patients with limited pulmonary disease who may be candidates for local therapies (15,16).

Management of Pulmonary Toxicities:-

Immune checkpoint inhibitors are associated with immune-related adverse events, including pneumonitis. Differentiating immune-related pneumonitis from disease progression or infection is critical, particularly in patients with pulmonary metastases (17). Prompt recognition and appropriate management, including treatment interruption and corticosteroid therapy when indicated, are essential to minimize morbidity while preserving oncologic outcomes.

Future Directions:

Future research should prioritize the inclusion of organ-specific endpoints in clinical trials, improved characterization of the pulmonary tumor microenvironment, and the identification of predictive biomarkers of response (15). Emerging translational data suggest that pulmonary metastases may exhibit distinct immune microenvironment features, including higher immune cell infiltration and specific angiogenic patterns, which could partly explain differential treatment responses (15). Advances in spatial transcriptomics, circulating biomarkers, radiomics, and artificial intelligence–assisted imaging analysis may further clarify organ-specific tumor behavior and treatment response in metastatic RCC (15,17). In parallel, the development of novel therapeutic combinations and biomarker-driven strategies is expected to refine patient selection and optimize the management of pulmonary metastatic disease (17).

Limitations of This Review:

This review is limited by its narrative design and the heterogeneity of available evidence. Many data supporting local treatment strategies are retrospective and subject to selection bias (11,13). Nevertheless, this review provides a comprehensive and clinically oriented synthesis of current evidence relevant to pulmonary metastatic RCC.




Figure 1. Therapeutic algorithm for the management of pulmonary metastatic renal cell carcinoma. This figure represents a simplified conceptual framework intended to support clinical decision-making and does not replace individualized multidisciplinary evaluation.

Ref.	Author (year)	Study design	Population	Treatment	Key lung-related findings
5	Dabestani et al. (2014)	Systematic review	Metastatic RCC	Local therapies	Survival benefit in selected patients
7	Hofmann et al. (2005)	Retrospective cohort	RC lung metastases	Metastasectomy	Five-year OS \approx 45%
9	Motzer et al. (2018)	Phase III RCT	Metastatic RCC	Nivolumab + ipilimumab	Durable pulmonary responses and OS benefit
10	Rini et al. (2019)	Phase III RCT	Metastatic RCC	Pembrolizumab + axitinib	Rapid tumor shrinkage in lung lesions
11	Choueiri et al. (2021)	Phase III RCT	Metastatic RCC	Nivolumab + cabozantinib	Improved PFS and OS in lung-dominant disease
12	Motzer et al. (2021)	Phase III RCT	Metastatic RCC	Pembrolizumab + lenvatinib	High objective response rate in pulmonary metastases
14	Tree et al. (2013)	Prospective series	Oligometastatic RCC	SBRT	Local control > 90%

Table 1. Major studies on pulmonary metastases from renal cell carcinoma

Conclusion:-

Pulmonary metastatic RCC is a common and clinically significant condition with favorable responsiveness to modern systemic therapies. Immunotherapy-based combinations have become the cornerstone of treatment and have significantly improved patient outcomes (10,13). Selected patients with lung-dominant oligometastatic disease may benefit from the integration of local therapies (15,16). Continued multidisciplinary collaboration and future research focusing on organ-specific outcomes are essential to further optimize management strategies.

References:-

1. Sung H, Ferlay J, Siegel RL, et al. CA Cancer J Clin. 2021;71:209–249.
2. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. Eur Urol. 2023;84:1–20.
3. Motzer RJ, Jonasch E, Agarwal N, et al. J Natl ComprCancNetw. 2024;22:1–18.
4. Escudier B, Porta C, Schmidinger M, et al. Ann Oncol. 2019;30:706–720.
5. Dabestani S, Marconi L, Hofmann F, et al. Lancet Oncol. 2014;15:e549–e561.
6. Heng DY, Xie W, Regan MM, et al. J Clin Oncol. 2009;27:5794–5799.
7. Hofmann HS, Neef H, Krohe K, et al. Eur Urol. 2005;48:77–81.
8. Kroege N, Choueiri TK, Lee JL, et al. Eur Urol. 2013;63:72–79.
9. Motzer RJ, Tannir NM, McDermott DF, et al. N Engl J Med. 2018;378:1277–1290.
10. Rini BI, Plimack ER, Stus V, et al. N Engl J Med. 2019;380:1116–1127.
11. Choueiri TK, Powles T, Burotto M, et al. N Engl J Med. 2021;384:829–841.
12. Motzer RJ, Alekseev B, Rha SY, et al. N Engl J Med. 2021;384:1289–1300.
13. Hellman S, Weichselbaum RR. J Clin Oncol. 1995;13:8–10.
14. Tree AC, Khoo VS, Eeles RA, et al. Lancet Oncol. 2013;14:e28–e37.
15. McDermott DF, Huseni MA, Atkins MB, et al. Nat Med. 2018;24:749–757.
16. Chiou VL, Burotto M. J Clin Oncol. 2015;33:3541–3543.
17. Choueiri TK, Bauer TM, Papadopoulos KP, et al. N Engl J Med. 2021;384:648–659.